文章摘要
刘晓慧,张赞玲,袁雪峰,等.利奈唑胺致重症肺部感染病人血小板减少的危险因素分析[J].安徽医药,2019,23(10):2108-2111.
利奈唑胺致重症肺部感染病人血小板减少的危险因素分析
Risk factors of thrombocytopenia induced by linezolid in severe pulmonary infection
  
DOI:10.3969/j.issn.1009?6469.2019.10.052
中文关键词: 血小板减少  呼吸道感染  横断面研究  利奈唑胺  logistic模型
英文关键词: Thrombocytopenia  Respiratory tract infections  Cross?sectional studies  Linezolid  Logistic model
基金项目:湖南省卫生健康委员会科研计划课题项目( 20180571)
作者单位
刘晓慧 长沙市第一医院药剂科湖南长沙 410005 
张赞玲 中南大学湘雅医院药学部湖南长沙 410008 
袁雪峰 长沙市第一医院药剂科湖南长沙 410005 
汤渝玲 长沙市第一医院药剂科湖南长沙 410005 
何鸽飞 长沙市第一医院药剂科湖南长沙 410005 
张顺芝 长沙市第一医院药剂科湖南长沙 410005 
李燕飞 长沙市第一医院药剂科湖南长沙 410005 
摘要点击次数: 2058
全文下载次数: 626
中文摘要:
      目的探讨重症肺部感染病人接受利奈唑胺治疗引起血小板减少症的危险因素。方法采用回顾性研究,收集 2016年 1月 1日至 2017年 12月 31日长沙市第一医院诊断为重症肺部感染接受利奈唑胺治疗的全部住院病人的资料,比较发生血小板减少组与未发生组差异,运用 logistic单因素和多因素回归分析血小板降低的危险因素。结果 173例病人(男性 138例,女性 35例)纳入研究, 53例病人( 30.6%)发生血小板减少症。 logistic模型分析显示,用药时间( OR=1.12;95%CI:1.05~1.20;P<0.05)是重症肺部感染病人使用利奈唑胺发生血小板减少症的独立危险因素,用药前血小板值( OR=0.99;95%CI:0.98~ 0.99;P<0.05)、用药前白蛋白( OR=0.84;95%CI:0.77~0.93;P<0.05)是发生血小板减少症的独立保护因素。结论利奈唑胺用药时间与重症肺部感染病人血小板减少密切相关,病人用药前白蛋白水平、血小板水平影响血小板减少症发生。
英文摘要:
      Objective To investigate the risk factors of thrombocytopenia in patients with severe pulmonary infection treated with li? nezolid.Methods A retrospective study was conducted to collect data from all hospitalized patients who were diagnosed with se?vere pulmonary infection and treated with linezolid in The First Hospital of Changsha from January 1,2016 to December 31,2017. The differences were compared between the two groups with thrombocytopenia and without thrombocytopenia.The risk factors ofthrombocytopenia were analyzed by logistic regression analysis.Results 173 patients(138 males and 35 females)were included in the study.53 patients(30.6%)developed thrombocytopenia.Logistic model analysis showed that time of medication(OR=1.12; 95%CI:1.051?1.20;P<0.05)was risk factors for thrombocytopenia in patients with severe pulmonary infection treated with linezol? id.The platelet value(OR=0.99;95%CI:0.98-0.99;P<0.05)and albumin concentration before treatment(OR=0.84;95%CI: 0.771?0.93;P<0.05)were known as protective factors for thrombocytopenia in patients who received linezolid therapy.Conclusion Medication time,albumin concentration and platelet value before treatment are associated with linezolid?induced thrombocytopeniain severe pulmonary infection.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮